RU2017106795A - Новые составы ингибитора тирозинкиназы брутона - Google Patents

Новые составы ингибитора тирозинкиназы брутона Download PDF

Info

Publication number
RU2017106795A
RU2017106795A RU2017106795A RU2017106795A RU2017106795A RU 2017106795 A RU2017106795 A RU 2017106795A RU 2017106795 A RU2017106795 A RU 2017106795A RU 2017106795 A RU2017106795 A RU 2017106795A RU 2017106795 A RU2017106795 A RU 2017106795A
Authority
RU
Russia
Prior art keywords
mass
composition
ibrutinib
solid dispersion
spray
Prior art date
Application number
RU2017106795A
Other languages
English (en)
Russian (ru)
Other versions
RU2017106795A3 (enExample
Inventor
Кассандра ШУ
Хариша АЛТУРИ
Роберт КУЕЛЬ
Пёрл Шве-Чо ТАЙ
Райан Митчел МИНИКИС
Джеймс Фрэнсис ХУЛВАТ
Александр Якоб МАКВЕЙ
Чин Ва ЧОН
Original Assignee
Фармасайкликс Элэлси
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Фармасайкликс Элэлси filed Critical Фармасайкликс Элэлси
Publication of RU2017106795A publication Critical patent/RU2017106795A/ru
Publication of RU2017106795A3 publication Critical patent/RU2017106795A3/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
RU2017106795A 2014-08-07 2015-08-07 Новые составы ингибитора тирозинкиназы брутона RU2017106795A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462034353P 2014-08-07 2014-08-07
US62/034,353 2014-08-07
PCT/US2015/044258 WO2016022942A1 (en) 2014-08-07 2015-08-07 Novel formulations of a bruton's tyrosine kinase inhibitor

Publications (2)

Publication Number Publication Date
RU2017106795A true RU2017106795A (ru) 2018-09-07
RU2017106795A3 RU2017106795A3 (enExample) 2019-04-12

Family

ID=55264642

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2017106795A RU2017106795A (ru) 2014-08-07 2015-08-07 Новые составы ингибитора тирозинкиназы брутона

Country Status (13)

Country Link
US (4) US9545407B2 (enExample)
EP (1) EP3193877A4 (enExample)
JP (1) JP2017523206A (enExample)
KR (1) KR20170033358A (enExample)
CN (1) CN106573002A (enExample)
AU (1) AU2015300798A1 (enExample)
BR (1) BR112017002231A2 (enExample)
CA (1) CA2955747A1 (enExample)
IL (1) IL250085A0 (enExample)
MX (1) MX2017001671A (enExample)
RU (1) RU2017106795A (enExample)
SG (1) SG11201700849XA (enExample)
WO (1) WO2016022942A1 (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ772688A (en) 2010-06-03 2022-09-30 Pharmacyclics Llc The use of inhibitors of bruton’s tyrosine kinase (btk)
WO2013184572A1 (en) 2012-06-04 2013-12-12 Pharmacyclics, Inc. Crystalline forms of a bruton's tyrosine kinase inhibitor
AU2013293087B2 (en) 2012-07-24 2017-08-31 Pharmacyclics Llc Mutations associated with resistance to inhibitors of Bruton's tyrosine kinase (BTK)
US9545407B2 (en) * 2014-08-07 2017-01-17 Pharmacyclics Llc Formulations of a bruton's tyrosine kinase inhibitor
IL315294A (en) * 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of bruton's tyrosine kinase inhibitor
PL3892302T3 (pl) * 2015-04-06 2024-03-11 Janssen Pharmaceutica Nv Kompozycje zawierające ibrutynib
CN108472259A (zh) * 2016-01-19 2018-08-31 詹森药业有限公司 包含btk抑制剂的配制品/组合物
AU2018257901A1 (en) * 2017-04-24 2019-11-14 Samus Therapeutics, Inc. Hsp90 inhibitor oral formulations and related methods
CN107014943B (zh) * 2017-06-07 2018-08-21 福建省微生物研究所 一种依鲁替尼对映异构体的检测方法
RS63046B1 (sr) * 2017-06-30 2022-04-29 Acrotech Biopharma Llc Nove oralne formulacije belinostata
US11304945B2 (en) * 2017-07-04 2022-04-19 Jiangsu Hengrui Medicine Co., Ltd. Pharmaceutical composition and method for preparing same
SG11202001129VA (en) * 2017-08-11 2020-03-30 Merck Patent Gmbh Pharmaceutical preparation comprising 3-fluoro-4-[7-methoxy-3-methyl-8-(1-methyl-1 h-pyrazol-4-yl)-2-oxo-2,3-dihydro-imidazo[4,5-c]quinolin-1 -yl]-benzonitrile
EP3684367A1 (en) 2017-09-19 2020-07-29 Cipla Limited Compositions comprising ibrutinib and an alkaloid having enhanced bioavailability
WO2019070698A1 (en) 2017-10-02 2019-04-11 Johnson Matthey Public Limited Company Novel forms of ibrutinib
WO2019091438A1 (zh) * 2017-11-10 2019-05-16 苏州信诺维医药科技有限公司 作为btk抑制剂的5-氨基吡唑甲酰胺化合物的无定型固体分散体
CZ2017787A3 (cs) * 2017-12-08 2019-06-19 Zentiva, K.S. Farmaceutické kompozice obsahující ibrutinib
CA3089537A1 (en) 2018-01-20 2019-07-25 Natco Pharma Limited Pharmaceutical compositions comprising ibrutinib
EP3746059B1 (en) 2018-01-31 2026-03-04 Deciphera Pharmaceuticals, LLC Combination therapy for the treatment of gastrointestinal stromal tumors
AU2019216351B2 (en) 2018-01-31 2024-07-25 Deciphera Pharmaceuticals, Llc Combination therapy for the treatment of mastocytosis
WO2019195827A1 (en) 2018-04-06 2019-10-10 Johnson Matthey Public Limited Company Novel form of ibrutinib
JP7410877B2 (ja) 2018-05-03 2024-01-10 ジュノー セラピューティクス インコーポレイテッド キメラ抗原受容体(car)t細胞療法とキナーゼ阻害剤の併用療法
KR20250125432A (ko) 2018-06-15 2025-08-21 얀센 파마슈티카 엔브이 이브루티닙을 포함하는 제형/조성물
CA3224985C (en) * 2018-07-31 2025-11-18 Loxo Oncology, Inc. SPRAY-DRIED DISPERSIONS, FORMULATIONS AND POLYMORPHIES OF (S)-5-AMINO-3-(4-((5-FLUORO-2-METHOXYBENZAMIDO)METHYL)PHENYL)(1,1,1-TRIFLUOROPROPANE-2-YL)-1H-PYRAZOLE-4-CARBOXAMIDE
WO2020185812A1 (en) 2019-03-11 2020-09-17 Teva Pharmaceuticals International Gmbh Solid state forms of ripretinib
MX2021012310A (es) 2019-04-11 2021-11-12 Goldfinch Bio Inc Formulación de secado por aspersión de un inhibidor de trpc5 de piridazinona.
US20220251105A1 (en) * 2019-05-17 2022-08-11 Celgene Car Llc Methods of treating a mk2-mediated disorder
FI4013412T3 (fi) 2019-08-12 2026-03-24 Deciphera Pharmaceuticals Llc Ripretinibi ruoansulatuskanavan stroomakasvaimien hoitoon
WO2021056048A1 (en) * 2019-09-23 2021-04-01 Bionomics Limited Therapeutic formulations and uses thereof
PL4084779T3 (pl) 2019-12-30 2025-02-24 Deciphera Pharmaceuticals, Llc Kompozycje 1-(4-bromo-5-(1-etylo-7-(metyloamino)-2-okso-1,2-dihydro-1,6-naftyrydyn-3-ylo)-2-fluorofenylo)-3-fenylomocznika
AU2020419197B2 (en) * 2019-12-30 2023-08-31 Deciphera Pharmaceuticals, Llc Amorphous kinase inhibitor formulations and methods of use thereof
BR112022019846A2 (pt) 2020-04-03 2022-11-22 Genentech Inc Método de tratamento de esclerose múltipla recorrente (rms), métodos para reduzir a taxa de recorrência anualizada (arr), reduzir o risco de experimentar ccdp12 e aumentar o tempo até o início de ccdp12 e compostos
IL297776A (en) * 2020-04-30 2022-12-01 Nanocopoeia Llc Orally disintegrating tablets containing an amorphous solid dispersion of nalotinib
CN111617028A (zh) * 2020-07-14 2020-09-04 扬子江药业集团江苏紫龙药业有限公司 一种含伊布替尼的口服制剂及制备方法
CA3202761A1 (en) 2020-11-25 2022-06-02 Nanocopoeia, Llc Amorphous cabozantinib particles and uses thereof
CN114681424A (zh) * 2020-12-31 2022-07-01 鲁南制药集团股份有限公司 一种伊布替尼胶囊及其制备方法
US11529351B2 (en) * 2021-01-21 2022-12-20 Xspray Pharma Ab Fast dissolving pharmaceutical compositions
US20240024248A1 (en) * 2021-01-21 2024-01-25 Xspray Pharma Ab Fast dissolving pharmaceutical compositions
CN116916893A (zh) * 2021-03-03 2023-10-20 奥克伍德实验室有限责任公司 包含btk抑制剂的微球制剂及其制备和使用方法
CN113509443B (zh) * 2021-07-14 2023-04-11 药源生物科技(启东)有限公司 一种含soluplus的固分体及其制备方法
WO2023104808A1 (en) * 2021-12-10 2023-06-15 Synthon B.V. Pharmaceutical composition comprising ibrutinib
US20250302954A1 (en) 2022-05-11 2025-10-02 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
CN115054603A (zh) * 2022-06-20 2022-09-16 上海宣泰医药科技股份有限公司 依鲁替尼药物组合物及其制备方法和药物制剂

Family Cites Families (157)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3303707A1 (de) 1983-02-04 1984-08-09 Dynamit Nobel Ag, 5210 Troisdorf Verfahren zur spaltung von organosiloxanen und dessen produkte und anwendungen
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
JPH01167840A (ja) 1987-12-24 1989-07-03 Konica Corp 新規な写真用シアンカプラー
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
GB9226855D0 (en) 1992-12-23 1993-02-17 Erba Carlo Spa Vinylene-azaindole derivatives and process for their preparation
US6326469B1 (en) 1994-04-22 2001-12-04 Sugen, Inc. Megakaryocytic protein tyrosine kinases
US5593997A (en) 1995-05-23 1997-01-14 Pfizer Inc. 4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors
CH690773A5 (de) 1996-02-01 2001-01-15 Novartis Ag Pyrrolo(2,3-d)pyrimide und ihre Verwendung.
AU3176297A (en) 1996-06-25 1998-01-14 Novartis Ag Substituted 7-amino-pyrrolo{3,2-d}pyrimidines and the use thereof
TR199902301T2 (xx) 1997-03-19 1999-12-21 Basf Aktiengesellschaft Pirilo $2,3D]pirimidinler ve onlar�n kullan�m�.
DK0901786T3 (da) * 1997-08-11 2007-10-08 Pfizer Prod Inc Faste farmaceutiske dispersioner med foröget biotilgængelighed
EP1039909B1 (en) * 1997-12-31 2002-10-09 Choongwae Pharma Corporation Method of production and composition of an oral preparation of itraconazole
US6303652B1 (en) 1998-08-21 2001-10-16 Hughes Institute BTK inhibitors and methods for their identification and use
WO1999054286A2 (en) 1998-04-17 1999-10-28 Parker Hughes Institute Btk inhibitors and methods for their identification and use
US6998233B2 (en) 1998-06-26 2006-02-14 Sunesis Pharmaceuticals, Inc. Methods for ligand discovery
US20050287596A9 (en) 1998-06-26 2005-12-29 Braisted Andrew C Novel ligands and libraries of ligands
US6335155B1 (en) 1998-06-26 2002-01-01 Sunesis Pharmaceuticals, Inc. Methods for rapidly identifying small organic molecule ligands for binding to biological target molecules
UA74141C2 (uk) 1998-12-09 2005-11-15 Дж.Д. Сірл Енд Ко. Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти)
EP1027886B1 (en) * 1999-02-10 2008-07-09 Pfizer Products Inc. Pharmaceutical solid dispersions
US6306897B1 (en) 1999-03-19 2001-10-23 Parker Hughes Institute Calanolides for inhibiting BTK
KR20020088406A (ko) 1999-09-17 2002-11-27 애보트 게엠베하 운트 콤파니 카게 치료제로서의 피라졸로피리미딘
US6921763B2 (en) 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
ATE277044T1 (de) 1999-10-06 2004-10-15 Boehringer Ingelheim Pharma Heterocyclische verbindungen verwendbar als tyrosinkinase inhibitoren
US6506769B2 (en) 1999-10-06 2003-01-14 Boehringer Ingelheim Pharmaceuticals, Inc. Heterocyclic compounds useful as inhibitors of tyrosine kinases
JP2003516351A (ja) 1999-11-30 2003-05-13 パーカー ヒューズ インスティテュート コラーゲン誘導血小板凝集阻害剤
JP2003532632A (ja) 1999-12-17 2003-11-05 アライアッド・ファーマシューティカルズ・インコーポレーテッド 新規の複素環
GB0005345D0 (en) 2000-03-06 2000-04-26 Mathilda & Terence Kennedy Ins Methods of treating sepsis septic shock and inflammation
GB0108903D0 (en) 2000-10-05 2001-05-30 Aventis Pharm Prod Inc Novel crystalline forms of a factor Xa inhibitor
CA2426508A1 (en) 2000-10-23 2002-05-16 Bristol-Myers Squibb Company Modulators of bruton's tyrosine kinase and bruton's tyrosine kinase intermediates and methods for their identification and use in the treatment and prevention of osteoporosis and related disease states
WO2002045684A2 (en) 2000-12-06 2002-06-13 Pharmacia Corporation Rapidly dispersing pharmaceutical composition comprising effervescent agents
ATE307571T1 (de) * 2001-02-27 2005-11-15 Pharmazeutische formulierung enthaltend bicalutamid
MXPA03008560A (es) 2001-03-22 2004-06-30 Abbot Gmbh & Co Kg Pirazolopirimidinas como agentes terapeuticos.
US8306897B2 (en) 2001-05-04 2012-11-06 Stockshield, Inc. Method and system for insuring against investment loss
EP1463742A4 (en) 2001-06-21 2006-05-10 Ariad Pharma Inc NEW PYRAZOLO AND PYRROLO PYRIMIDINES AND THEIR USES
CN1523991A (zh) 2001-08-10 2004-08-25 ��˹��ŵ�� 单独的c-Src抑制剂或其与STI571的组合用于治疗白血病的用途
EP1425577A4 (en) 2001-08-10 2004-12-29 Symyx Technologies Inc APPARATUSES AND METHODS FOR PREPARING AND TESTING PRE-FORMULATIONS AND CORRESPONDING SYSTEMS
WO2003016338A1 (en) 2001-08-15 2003-02-27 Parker Hughes Institute Crystal structure of the btk kinase domain
NZ532579A (en) 2001-11-21 2006-11-30 Sunesis Pharmaceuticals Inc Methods for ligand discovery based on tethering process
US20050084905A1 (en) 2002-03-21 2005-04-21 Prescott John C. Identification of kinase inhibitors
GB2388594A (en) 2002-05-16 2003-11-19 Bayer Ag Imidazo-triazine PDE 4 inhibitors
EP1529046A1 (en) 2002-08-08 2005-05-11 Boehringer Ingelheim Pharmaceuticals Inc. Substituted benzimidazole compounds
GB0303910D0 (en) 2003-02-20 2003-03-26 Merck Sharp & Dohme Therapeutic agents
US7687506B2 (en) 2003-04-11 2010-03-30 The Regents Of The University Of California Selective serine/threonine kinase inhibitors
WO2004100868A2 (en) 2003-04-23 2004-11-25 Abbott Laboratories Method of treating transplant rejection
EP1473039A1 (en) 2003-05-02 2004-11-03 Centre National De La Recherche Scientifique (Cnrs) Use of inhibitors and antisense oligonucleotides of BTK for the treatment of proliferative mastocytosis
WO2005014599A1 (en) 2003-06-04 2005-02-17 Cellular Genomics, Inc. Imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of bruton’s tyrosine kinase by such compounds
WO2005005429A1 (en) 2003-06-30 2005-01-20 Cellular Genomics, Inc. Certain heterocyclic substituted imidazo[1,2-a]pyrazin-8-ylamines and methods of inhibition of bruton’s tyrosine kinase by such compounds
US8591946B2 (en) * 2003-08-29 2013-11-26 Veloxis Pharmaceuticals A/S Modified release compositions comprising tacrolimus
US8131475B2 (en) 2003-09-03 2012-03-06 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Methods for identifying, diagnosing, and predicting survival of lymphomas
CN1897950A (zh) 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
ES2372694T3 (es) 2003-10-15 2012-01-25 OSI Pharmaceuticals, LLC Inhibidores de tirosina cinasa de imidazo[1,5-a]pirazina.
AU2003297904A1 (en) 2003-12-12 2005-07-14 University Of Maryland, Baltimore Immunomodulatory compounds that target and inhibit the py+3 binding site of tyrosene kinase p56 lck sh2 domain
US20050153990A1 (en) 2003-12-22 2005-07-14 Watkins William J. Phosphonate substituted kinase inhibitors
BRPI0418031A (pt) 2003-12-22 2007-04-17 Gilead Sciences Inc inibidores de quinase fosfonato-substituìdos
WO2005095406A1 (en) 2004-01-26 2005-10-13 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of protein kinases
CA2553724A1 (en) 2004-02-03 2005-08-18 Abbott Laboratories Aminobenzoxazoles as therapeutic agents
ITMI20041314A1 (it) 2004-06-30 2004-09-30 Nuvera Fuel Cells Europ Srl Dispositivo di raffreddamento per celle a combustibili a membrana
AR053090A1 (es) 2004-07-20 2007-04-25 Osi Pharm Inc Imidazotriazinas como inhibidores de proteina quinasas y su uso para la preparacion de medicamentos
US20060079494A1 (en) 2004-09-27 2006-04-13 Santi Daniel V Specific kinase inhibitors
EP1802602A1 (en) 2004-09-28 2007-07-04 Janssen Pharmaceutica N.V. Substituted dipiperdine ccr2 antagonists
EP1812442A2 (en) 2004-11-10 2007-08-01 CGI Pharmaceuticals, Inc. Imidazo[1,2-a]pyrazin-8-ylamines useful as modulators of kinase activity
GB0425035D0 (en) 2004-11-12 2004-12-15 Novartis Ag Organic compounds
KR101335932B1 (ko) 2005-03-07 2013-12-04 바이엘 헬스케어 엘엘씨 암의 치료를 위한 오메가-카르복시아릴 치환된 디페닐우레아를 포함하는 제약 조성물
WO2006099075A2 (en) 2005-03-10 2006-09-21 Cgi Pharmaceuticals, Inc. Certain substituted amides, method of making, and method of use thereof
DE602006019088D1 (de) 2005-05-13 2011-02-03 Irm Llc Verbindungen und zusammensetzungen als proteinkinase-hemmer
DK2395004T3 (en) 2005-06-22 2016-03-21 Plexxikon Inc Pyrrolo [2,3-b] pyridine derivatives as protein kinase inhibitors
US20070065449A1 (en) 2005-09-16 2007-03-22 Claire Verschraegen Method of treating cancer, especially soft tissue sarcoma utilizing gemcitabine in combination with docetaxel and anti-VEGF therapy (bevacizumab)
WO2007058832A2 (en) 2005-11-12 2007-05-24 Boehringer Ingelheim International Gmbh Pyrrolo (2, 3-b) pyridine derivatives useful as tec kinase inhibitors
BRPI0621027A2 (pt) 2006-01-13 2011-11-29 Pharmacyclics Inc composto, composição farmacêutica
EP1984030B1 (en) 2006-01-30 2013-05-08 The Scripps Research Institute Methods for detection of circulating tumor cells and methods of diagnosis of cancer in a mammalian subject
WO2007109604A2 (en) * 2006-03-20 2007-09-27 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions
EA200870409A1 (ru) 2006-04-04 2009-04-28 Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния Антагонисты киназы pi3
AU2007254179B2 (en) 2006-05-18 2013-03-21 Pharmacyclics Llc Intracellular kinase inhibitors
DE102006026583A1 (de) 2006-06-07 2007-12-13 Bayer Healthcare Aktiengesellschaft Aryl-substituierte hetero-bicyclische Verbindungen und ihre Verwendung
PL2526933T3 (pl) 2006-09-22 2015-08-31 Pharmacyclics Llc Inhibitory kinazy tyrozynowej Brutona
ES2403546T3 (es) 2006-11-03 2013-05-20 Pharmacyclics, Inc. Sonda de actividad de la tirosina-cinasa de Bruton y procedimiento de utilización
NL2000640C2 (nl) 2007-03-05 2008-09-08 Stichting Wetsus Ct Of Excelle Werkwijze en systeem voor het zuiveren van een vloeistof.
US20120101113A1 (en) 2007-03-28 2012-04-26 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
SG10201508035TA (en) 2007-03-28 2015-10-29 Pharmacyclics Inc Inhibitors of bruton's tyrosine kinase
US20120065201A1 (en) 2007-03-28 2012-03-15 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
US20090010911A1 (en) 2007-04-06 2009-01-08 Iowa State University Research Foundation, Inc. Methods and compositions for affecting cyclophilin a regulation of kinases in modulating cellular activities
US7982036B2 (en) 2007-10-19 2011-07-19 Avila Therapeutics, Inc. 4,6-disubstitued pyrimidines useful as kinase inhibitors
JP5587193B2 (ja) 2007-10-23 2014-09-10 エフ.ホフマン−ラ ロシュ アーゲー 新規なキナーゼ阻害剤
US8426441B2 (en) 2007-12-14 2013-04-23 Roche Palo Alto Llc Inhibitors of bruton's tyrosine kinase
US20150152115A1 (en) 2007-12-27 2015-06-04 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
JP5714910B2 (ja) 2008-01-09 2015-05-07 チャールストン ラボラトリーズ,インコーポレイテッド 薬学的組成物
US8808742B2 (en) 2008-04-14 2014-08-19 Ardea Biosciences, Inc. Compositions and methods for preparing and using same
EP2123626A1 (en) 2008-05-21 2009-11-25 Laboratorios del Dr. Esteve S.A. Co-crystals of duloxetine and co-crystal formers for the treatment of pain
NZ603525A (en) 2008-06-27 2015-02-27 Celgene Avilomics Res Inc Pyrimidine based compound and uses thereof
CA2730930C (en) 2008-07-16 2015-01-13 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors
JP2012504553A (ja) 2008-07-29 2012-02-23 フロンティア サイエンティフィック インコーポレイテッド 微生物の殺滅または増殖抑制のためのテトラキス(n−アルキルピリジニウム)−ポルフィリン誘導体の使用
US8426428B2 (en) 2008-12-05 2013-04-23 Principia Biopharma, Inc. EGFR kinase knockdown via electrophilically enhanced inhibitors
WO2010068806A1 (en) 2008-12-10 2010-06-17 Cgi Pharmaceuticals, Inc. Amide derivatives as btk inhibitors in the treatment of allergic, autoimmune and inflammatory disorders as well as cancer
WO2010126960A1 (en) 2009-04-29 2010-11-04 Locus Pharmaceuticals, Inc. Pyrrolotriazine compounds
US9556426B2 (en) 2009-09-16 2017-01-31 Celgene Avilomics Research, Inc. Protein kinase conjugates and inhibitors
US7741330B1 (en) 2009-10-12 2010-06-22 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase
MX2012013622A (es) 2010-05-31 2013-02-01 Ono Pharmaceutical Co Derivado de purinona.
NZ772688A (en) 2010-06-03 2022-09-30 Pharmacyclics Llc The use of inhibitors of bruton’s tyrosine kinase (btk)
US20120071497A1 (en) 2010-06-03 2012-03-22 Pharmacyclics, Inc. Methods of treating abc-dlbcl using inhibitors of bruton's tyrosine kinase
CA2803056C (en) 2010-06-23 2017-05-16 Hanmi Science Co., Ltd. Fused pyrimidine derivatives for inhibition of tyrosine kinase activity
CN105566229A (zh) 2010-08-10 2016-05-11 西建阿维拉米斯研究公司 Btk抑制剂的苯磺酸盐及其用途和制备方法
US8541391B2 (en) 2010-10-28 2013-09-24 Viropharma Incorporated Crystalline phases of 5,6-dichloro-2-(isopropylamino)-1-β-L-ribofuranosyl-1H-benzimidazole
US8501484B2 (en) 2011-03-14 2013-08-06 Los Alamos National Security, Llc Preparation of cerium halide solvate complexes
MX2011004759A (es) 2011-05-04 2012-11-21 Senosiain S A De C V Lab Nuevas formas solidas de antibioticos.
EA025496B1 (ru) 2011-05-17 2016-12-30 Принсипиа Биофарма Инк. Ингибиторы тирозинкиназы
CN103813794A (zh) 2011-07-18 2014-05-21 拓凯制药公司 用于治疗前列腺癌的新型组合物及方法
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
DK3181122T3 (da) * 2012-01-13 2023-06-06 Xspray Pharma Ab Publ Farmaceutisk dasatinib-sammensætning
US8501724B1 (en) 2012-01-31 2013-08-06 Pharmacyclics, Inc. Purinone compounds as kinase inhibitors
JP5514256B2 (ja) 2012-05-18 2014-06-04 株式会社東芝 磁気記憶素子及びその製造方法
WO2013184572A1 (en) 2012-06-04 2013-12-12 Pharmacyclics, Inc. Crystalline forms of a bruton's tyrosine kinase inhibitor
DK2861599T3 (da) 2012-06-18 2020-03-02 Principia Biopharma Inc Reversible kovalente pyrrolo- eller pyrazolopyrimidiner, der er nyttige til behandling af cancer og autoimmunsygdomme
WO2014004707A1 (en) 2012-06-29 2014-01-03 Principia Biopharma Inc. Formulations comprising ibrutinib
AU2013293087B2 (en) 2012-07-24 2017-08-31 Pharmacyclics Llc Mutations associated with resistance to inhibitors of Bruton's tyrosine kinase (BTK)
CN103121999A (zh) 2012-08-29 2013-05-29 苏州迪飞医药科技有限公司 一种酪氨酸激酶抑制剂pci-32765的合成方法
SG11201503842PA (en) 2012-11-15 2015-06-29 Pharmacyclics Inc Pyrrolopyrimidine compounds as kinase inhibitors
ES2834638T3 (es) 2013-05-30 2021-06-18 Infinity Pharmaceuticals Inc Tratamiento de cánceres usando moduladores de isoforma de PI3 cinasa
US20160067241A1 (en) 2013-06-13 2016-03-10 Dennis M. Brown Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted naphthalimides such as amonafide for the treatment of immunological, metabolic, infectious, and benign or neoplastic hyperproliferative disease conditions
US9421208B2 (en) 2013-08-02 2016-08-23 Pharmacyclics Llc Methods for the treatment of solid tumors
WO2015034478A1 (en) 2013-09-04 2015-03-12 Halliburton Energy Services, Inc. Scale-inhibiting cocrystals for treatment of a subterranean formation
CA3206628A1 (en) 2013-09-12 2015-03-19 Dana-Farber Cancer Institute, Inc. Methods for evaluating and treating waldenstrom's macroglobulinemia
TWI617309B (zh) 2013-10-25 2018-03-11 製藥公司 使用布魯頓氏酪胺酸激酶抑制劑之治療及免疫療法
WO2015071432A1 (en) 2013-11-14 2015-05-21 Sandoz Ag Pharmaceutical compositions of ibrutinib
CN103694241A (zh) 2013-11-27 2014-04-02 苏州晶云药物科技有限公司 Pci-32765的新晶型a及其制备方法
US20160310417A1 (en) 2013-12-20 2016-10-27 Emory University Formulations and Methods For Targeted Ocular Delivery of Therapeutic Agents
CN106008521A (zh) 2014-01-29 2016-10-12 苏州晶云药物科技有限公司 依鲁替尼的新晶型及其制备方法
WO2015120110A2 (en) 2014-02-07 2015-08-13 Auspex Pharmaceuticals, Inc. Novel pharmaceutical formulations
US20150231077A1 (en) 2014-02-17 2015-08-20 The Cleveland Clinic Foundation Amine passivated nanoparticles for cancer treatment and imaging
WO2015127261A1 (en) 2014-02-21 2015-08-27 Pharmacyclics, Inc. Biomarkers for predicting response of dlbcl to treatment with ibrutinib
US20150267752A1 (en) 2014-03-19 2015-09-24 Roller Bearing Company Of America, Inc. Bearing outer race having a radially inwardly biased seal
CA2942528A1 (en) 2014-03-20 2015-09-24 Pharmacyclics Inc. Phospholipase c gamma 2 and resistance associated mutations
US9884869B2 (en) 2014-03-27 2018-02-06 Perrigo Api Ltd. Ibrutinib solid forms and production process therefor
CN105085529A (zh) 2014-05-15 2015-11-25 广东东阳光药业有限公司 依鲁替尼新晶型及其制备方法
US9127069B1 (en) 2014-06-11 2015-09-08 Antecip Bioventures LLC Compositions comprising rank/rankl antagonists and related compounds for treating pain
US20150110871A1 (en) 2014-06-02 2015-04-23 David Wong Gastric retentive tablet compositions
US20160008777A1 (en) 2014-07-09 2016-01-14 Novotec Consulting Inc. Pharmaceutical compounding kit
PT107846B (pt) 2014-08-01 2019-03-22 Hovione Farm S A Produção de nano- partículas de dispersões sólidas amorfas por co-precipitação controlada
WO2016020697A1 (en) 2014-08-06 2016-02-11 Cipla Limited Pharmaceutical compositions of polymeric nanoparticles
US9545407B2 (en) 2014-08-07 2017-01-17 Pharmacyclics Llc Formulations of a bruton's tyrosine kinase inhibitor
EP3180343A1 (en) 2014-08-14 2017-06-21 Assia Chemical Industries Ltd. Solid state forms of ibrutinib
EP3201197B1 (en) 2014-10-01 2019-03-27 ratiopharm GmbH Acid addition salt of ibrutinib
CN104523695A (zh) 2014-11-12 2015-04-22 广东东阳光药业有限公司 一种治疗过度增生性疾病的药物组合物
CN105640961A (zh) 2014-11-18 2016-06-08 山东瑞禾医药科技有限公司 一种含依鲁替尼的药物组合物
WO2016079216A1 (en) 2014-11-20 2016-05-26 Sandoz Ag Physical forms of ibrutinib, a bruton's kinase inhibitor
US20150224060A1 (en) 2015-01-03 2015-08-13 David Wong Gastric retentive tablet compositions
CZ201584A3 (cs) 2015-02-09 2016-08-17 Zentiva, K.S. Sůl Ibrutinib sulfátu
JP2018511580A (ja) 2015-03-03 2018-04-26 ドクター レディズ ラボラトリーズ リミテッド イブルチニブの多形体
IL315294A (en) 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of bruton's tyrosine kinase inhibitor
JP6705833B2 (ja) 2015-04-02 2020-06-03 ラティオファルム ゲー・エム・ベー・ハー イブルチニブとカルボン酸との共結晶
PL3892302T3 (pl) 2015-04-06 2024-03-11 Janssen Pharmaceutica Nv Kompozycje zawierające ibrutynib
CN105294696A (zh) 2015-11-19 2016-02-03 上海创诺医药集团有限公司 依鲁替尼新晶型及其制备方法
CN105440040B (zh) 2015-12-23 2018-03-13 浙江京新药业股份有限公司 依鲁替尼的纯化方法
CN105646498A (zh) 2016-03-01 2016-06-08 孙霖 依鲁替尼晶型f及制备方法
CN105646499A (zh) 2016-03-01 2016-06-08 孙霖 依鲁替尼晶型g及制备方法
CN105646484A (zh) 2016-03-01 2016-06-08 孙霖 晶型b及制备方法
CN106619643A (zh) 2016-11-11 2017-05-10 上海雅本化学有限公司 一种含依鲁替尼的药物组合物

Also Published As

Publication number Publication date
US20160038496A1 (en) 2016-02-11
BR112017002231A2 (pt) 2018-07-17
WO2016022942A1 (en) 2016-02-11
KR20170033358A (ko) 2017-03-24
CA2955747A1 (en) 2016-02-11
US20180028537A1 (en) 2018-02-01
US20190282578A1 (en) 2019-09-19
RU2017106795A3 (enExample) 2019-04-12
SG11201700849XA (en) 2017-03-30
MX2017001671A (es) 2017-07-04
AU2015300798A1 (en) 2017-02-02
IL250085A0 (en) 2017-03-30
US9545407B2 (en) 2017-01-17
CN106573002A (zh) 2017-04-19
JP2017523206A (ja) 2017-08-17
EP3193877A1 (en) 2017-07-26
US20170079981A1 (en) 2017-03-23
EP3193877A4 (en) 2018-04-04

Similar Documents

Publication Publication Date Title
JP2017523206A5 (enExample)
JP2017525712A5 (enExample)
JP6301934B2 (ja) チカグレロルを含む固形経口医薬製剤
RU2017109139A (ru) Таблетки, содержащие большую дозу рукапариба
EP3606511A1 (en) Pharmaceutical composition comprising lenvatinib mesylate
TW201444589A (zh) 錠劑型式
RU2008119410A (ru) Диспергируемые таблетки, включающие деферасирокс
TWI592154B (zh) Allisartan-based solid dispersions and pharmaceutical compositions containing the solid dispersions
EP1711168A2 (en) Oral pharmaceutical compositions of candesartan cilexetil
CA2623018A1 (en) Pharmaceutical compositions of telmisartan
WO2005084648A1 (en) Pharmaceutical compositions comprising candesartan cilexetil
JP2017505313A5 (enExample)
RU2018126670A (ru) Фармацевтическая композиция для лечения гиперплазии предстательной железы
AU2016231883A1 (en) Pharmaceutical compositions of dimethyl fumarate
RU2709526C2 (ru) Фармацевтические композиции, которые содержат лобеглитазон, для перорального введения
KR20100083047A (ko) 생체이용률이 향상된 발사르탄을 포함하는 약제학적 조성물
JP7641098B2 (ja) リバーロキサバン含有錠剤
RU2016106328A (ru) Противотуберкулезная стабильная фармацевтическая композиция в форме диспергируемой таблетки, содержащей гранулированный изониазид и гранулированный рифапентин, и способ ее приготовления
KR20190038881A (ko) 무정형 소포스부비르를 포함하는 고체 제약 조성물
JP7511596B2 (ja) リバーロキサバン含有錠剤
MD4877C1 (ro) Compoziţie farmaceutică şi comprimat oral de S-adenozilmetionină cu eliberare întârziată
JP2017513878A (ja) 活性成分(i)含有組成物及びその製造方法
BR112014026040B1 (pt) Comprimido de liberação sustentada que contém levodropropizina
WO2014030172A2 (en) Pharmaceutical formulations of rufinamide
WO2013100878A1 (en) Pharmaceutical formulations comprising aripiprazole

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20191029